Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Organisation › Details

UCB S.A. (Euronext: UCB)

UCB, Brussels, Belgium ( is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB). *


Period Start 1928-01-01 established
  Group UCB (Group)
Products Industry pharmaceutical
  Industry 2 CNS drug
Person Person Tellier, Jean-Christophe (201403– CEO-elect joined UCB 2011 before Ipsen + Macrogenics + Novartis)
Region Region Brussels
  Country Belgium
  Street 60 Allée de la Recherche
  City 1070 Brussels
  Tel +32-2-559-9999
    Address record changed: 2020-12-02
Basic data Employees G: 5,001 to 10,000 (2017-12-31)
  Currency EUR
  Annual sales 4,632,000,000 (revenue, consolidated (2018) 2018-12-31)
  Profit 823,000,000 (2018-12-31)
  Cash 1,049,000,000 (2017-12-31)
    * Document for �About Section�: 
Record changed: 2021-04-04


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for UCB (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top